Skip to content

Efficacy and Mechanism Exploration of Imaxitinib in Psoriasis

Efficacy and Mechanism Exploration of Imaxitinib in Psoriasis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118539
Enrollment
Unknown
Registered
2026-02-06
Start date
2026-02-28
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Ivarmacitinib Sulfate Group:None

Sponsors

Binzhou Medical University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 18–75 years, regardless of gender. Patients meeting the diagnostic criteria, diagnosed by our department’s physicians as having moderate-to-severe plaque psoriasis based on clinical and pathological assessment, with baseline BSA =3, PASI =3, and DLQI =6.

Exclusion criteria

Exclusion criteria: Patients who are deemed ineligible for the trial by the investigator due to other reasons.

Design outcomes

Primary

MeasureTime frame
PASI 100;

Secondary

MeasureTime frame
IL-17, IL23, IL-22, TNF-a;

Countries

China

Contacts

Public Contactwangjing

The Affiliated Hospital of Binzhou Medical University

wj446533781@163.com+86 543 325 7792

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026